Issue 21, 2024

α-Aryl substituted GdDOTA derivatives, the perfect contrast agents for MRI?

Abstract

Enhancing the performance of Gd3+ chelates as relaxation agents for MRI has the potential to lower doses, improving safety and mitigating the environmental impact on our surface waters. More than three decades of research into manipulating the properties of Gd3+ have failed to develop a chelate that simultaneously optimizes all relevant parameters and affords maximal relaxivity. Introducing aryl substituents into the α-position of the pendant arms of a GdDOTA chelate affords chelates that, for the first time, simultaneously optimize all physico-chemical properties. Slowing tumbling by binding to human serum albumin affords a relaxivity of 110 ± 5 mM−1 s−1, close to the maximum possible. As discrete chelates, these α-aryl substituted GdDOTA chelates exhibit relaxivities that are 2–3 times higher than those of currently used agents, even at the higher fields (1.5 & 3.0 T) used in modern clinical MRI.

Graphical abstract: α-Aryl substituted GdDOTA derivatives, the perfect contrast agents for MRI?

Supplementary files

Article information

Article type
Communication
Submitted
08 Dec 2023
Accepted
08 Jan 2024
First published
09 Jan 2024
This article is Open Access
Creative Commons BY license

Chem. Commun., 2024,60, 2898-2901

α-Aryl substituted GdDOTA derivatives, the perfect contrast agents for MRI?

K. B. Maier, L. N. Rust, F. Carniato, M. Botta and M. Woods, Chem. Commun., 2024, 60, 2898 DOI: 10.1039/D3CC05989H

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements